Observational studyRheumatology (Oxford, England)2025
Achieving inactive disease state in men and women with axial spondyloarthritis: results from a multi-country prospective observational study.
Observational study in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE trials.Rheumatology (Oxford, England) · 2026Trial
- Clinical characteristics, comorbidities, and disease activity outcomes in a Saudi Arabian axial spondyloarthritis cohort.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo assess the probability of achieving low disease activity (LDA) and inactive disease (ID) in men vs women with recently diagnosed axial spondyloarthritis (axSpA).
methodsThis 1-year post-hoc analysis of the PROOF study assessed patients with recently diagnosed (≤12 months) axSpA. Patients were classified as having radiographic (r) or non-radiographic (nr) axSpA using central radiograph readings. Demographics, disease characteristics, and treatment were assessed at baseline and annually thereafter. Disease activity at 1 year was assessed by Axial Spondyloarthritis Disease Activity Score (ASDAS).
results1385 patients with baseline and year 1 data were included. Patients were classified as having nr-axSpA (n = 477 [34%]; 47% men) or r-axSpA (n = 908 [66%]; 71% men). Men had higher TNF inhibitor (TNFi) use vs women with nr-axSpA (15% vs 9%; P = 0.0238) and r-axSpA (20% vs 13%; P = 0.0118). At 1 year, TNFi use increased, remaining significantly higher for men with r-axSpA (34.9% vs 28.1%; P = 0.0497) but not nr-axSpA. Significantly more men with nr-axSpA achieved ASDAS LDA (46.0% vs 27.1%; P = 0.0002) and ID (21.7% vs 9.6%; P = 0.0013); no significant difference was observed in r-axSpA. Female sex was associated with significantly lower odds of achieving LDA and ID in nr-axSpA only (odds ratio, men vs women, LDA: 2.23 [95% CI, 1.45, 3.42]; ID: 2.40 [1.39, 4.12]).
conclusionWomen with nr-axSpA, but not r-axSpA, were less likely to achieve LDA and ID after 1 year than men. These data stress the need to carefully evaluate the diagnosis and causes of pain in patients diagnosed with axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.